$VTRS News

Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack

JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20

Viatris’ Dividend Has Room to Grow, but Will Management Deliver?

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment

Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults

Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade)

Viatris To Acquire Pacira BioSciences: What Investors Should Know

Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus

Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Should Value Investors Buy Viatris (VTRS) Stock?

UBS Maintains Buy on Viatris, Raises Price Target to $26

FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application

Harrow Closes Acquisition of TYRVAYA®

Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

Is Viatris Stock Outperforming the S&P 500?

Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25